ATProto Browser

Record data

{
  "uri": "at://did:plc:plgt5bqnko7dwhzi2436ipuf/app.bsky.feed.post/3llfcjsa3ik2v",
  "cid": "bafyreietdr2ouxxdfpm4ntqanbdedwtiuelcypsnqyf2avux5dx6vgdeai",
  "value": {
    "text": "Patients with Hodgkin lymphoma refractory/intolerant to both BV & checkpoint inhibitors (an increasing reality in the modern era) have median OS 7.4 yrs. This is a new benchmark in novel trials for R/R cHL. Thank you for the opportunity to participate! #lymsm #medsky\nwww.nature.com/articles/s41...",
    "$type": "app.bsky.feed.post",
    "embed": {
      "$type": "app.bsky.embed.images",
      "images": [
        {
          "alt": "",
          "image": {
            "$type": "blob",
            "ref": {
              "$link": "bafkreifkqtp7palrblkd77ftuwcculf44ih6dj5r4u73oc6zadomgjvjli"
            },
            "mimeType": "image/jpeg",
            "size": 357074
          },
          "aspectRatio": {
            "width": 804,
            "height": 458
          }
        }
      ]
    },
    "langs": [
      "en"
    ],
    "facets": [
      {
        "index": {
          "byteEnd": 259,
          "byteStart": 253
        },
        "features": [
          {
            "tag": "lymsm",
            "$type": "app.bsky.richtext.facet#tag"
          }
        ]
      },
      {
        "index": {
          "byteEnd": 267,
          "byteStart": 260
        },
        "features": [
          {
            "tag": "medsky",
            "$type": "app.bsky.richtext.facet#tag"
          }
        ]
      },
      {
        "index": {
          "byteEnd": 298,
          "byteStart": 268
        },
        "features": [
          {
            "uri": "https://www.nature.com/articles/s41408-025-01257-1",
            "$type": "app.bsky.richtext.facet#link"
          }
        ]
      }
    ],
    "createdAt": "2025-03-27T22:03:25.761Z"
  }
}